
UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer
AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Newsletters and Deep Dive digital magazine
AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Boehringer Ingelheim is preparing for multiple drug launches in the second half of 2025,
Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint inhibitor immunotherapy, significantly boosted anti-tumour activit
Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous formulation of DARZALEX
Scancell has the results it was hoping for with its melanoma immunotherapy iSCIB1+ and is accelerating plans for a pivotal trial.
Editor's Picks
Newsletters and Deep Dive
digital magazine